CIK 0001816736
- Large accelerated filer
Disc Medicine, Inc.
Sign in to watch- Ticker
- IRON
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 851612845
- Phone
- +1 617-674-9274
- Business address
- 321 ARSENAL STREET, SUITE 101, WATERTOWN, MA, 02472
- Former names
- Gemini Therapeutics, Inc. /DE, FS Development Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $11,877,065
- in 6 filings, $10.0M under 10b5-1 plans
Net −$11,877,065. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 32 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-23 | Atlas Venture Fund X, L.P. 10% owner | Sale | −82,500 | $67.65 | $5.6M | 703,660 |
| 2024-01-23 | Atlas Venture Fund X, L.P. 10% owner | Sale | −20,000 | $67.65 | $1.4M | 198,326 |
| 2024-01-10 | Bryce Joanne Chief Financial Officer | Grant or award | +18,165 | 23,665 | ||
| 2024-01-10 | Bryce Joanne Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +27,250 | 27,250 | ||
| 2024-01-10 | Quisel John D Chief Executive Officer | Grant or award | +66,365 | 69,065 | ||
| 2024-01-10 | Quisel John D Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +99,550 | 99,550 | ||
| 2024-01-10 | Khara Rahul General Counsel | Grant or award | +14,035 | 14,035 | ||
| 2024-01-10 | Khara Rahul General Counsel | Grant or award · Stock Option (Right to Buy) | +21,050 | 21,050 | ||
| 2024-01-10 | Yu Jonathan Yen-Wen Chief Business Officer | Grant or award | +18,165 | 18,165 | ||
| 2024-01-10 | Yu Jonathan Yen-Wen Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +27,250 | 27,250 | ||
| 2024-01-10 | Savage William Jacob Chief Medical Officer | Grant or award | +18,535 | 21,535 | ||
| 2024-01-10 | Savage William Jacob Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +27,800 | 27,800 | ||
| 2024-01-10 | Bitterman Kevin Director | Sale | −20,000 | $64.00 | $1.3M | 786,160 |
| 2024-01-10 | Atlas Venture Fund X, L.P. 10% owner | Sale | −30,000 | $64.00 | $1.9M | 1,449,686 |
| 2024-01-10 | Atlas Venture Fund X, L.P. 10% owner | Sale | −20,000 | $64.00 | $1.3M | 786,160 |
| 2023-12-29 | Quisel John D Chief Executive Officer | Option exercise | +2,700 | $1.01 | $3K | 2,700 |
| 2023-12-29 | Quisel John D Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −2,700 | 241,211 | ||
| 2023-12-27 | Bryce Joanne Chief Financial Officer | Option exercise | +3,000 | $9.86 | $30K | 5,500 |
| 2023-12-27 | Bryce Joanne Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −3,000 | 73,745 | ||
| 2023-12-18 | ORBIMED ADVISORS LLC Director | Option exercise | +1,724 | $38.00 | $66K | 1,724 |
Page 23 of 32 · 639 trades